^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EGFR806-specific CAR T-cell therapy

    i
    Company:
    Cellevolve Bio, Seattle Children's Hospital, Seattle Children’s Therapeutics
    Drug class:
    EGFR-targeted CAR-T immunotherapy
    Related drugs:
    4d
    Locoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical Trial. (PubMed, Neuro Oncol)
    Intracranially infused EGFR806-CAR T cells were tolerable at tested doses, with a best response of stable disease. EGFR is a potentially useful target for cellular therapy against pediatric brain tumors, particularly high-grade gliomas.
    P1 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR expression • EGFR wild-type
    |
    EGFR806-specific CAR T-cell therapy • depatuxizumab (ABT-806)
    3ms
    EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (clinicaltrials.gov)
    P1, N=11, Completed, Seattle Children's Hospital | Active, not recruiting --> Completed | Trial completion date: Mar 2040 --> Dec 2023 | Trial primary completion date: Mar 2025 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    EGFR806-specific CAR T-cell therapy
    11ms
    STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
    P1, N=44, Recruiting, Seattle Children's Hospital | Trial completion date: Jun 2038 --> Jun 2040 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19
    over1year
    STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
    P1, N=44, Recruiting, Seattle Children's Hospital | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial primary completion date • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    EGFR806-specific CAR T-cell therapy
    almost2years
    Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors (clinicaltrials.gov)
    P1, N=72, Recruiting, Seattle Children's Hospital | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    EGFR806-specific CAR T-cell therapy • SC-CAR4BRAIN
    2years
    EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Seattle Children's Hospital | Recruiting --> Active, not recruiting | N=36 --> 11
    Enrollment closed • Enrollment change • CAR T-Cell Therapy • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR positive
    |
    EGFR806-specific CAR T-cell therapy
    over2years
    EGFR as a potent CAR T target in triple negative breast cancer brain metastases. (PubMed, Breast Cancer Res Treat)
    Our results demonstrates anti-tumor activity of EGFR806 CAR T cells against TNBC cells in vitro and in vivo. Given EGFR806 CAR T cells are currently undergoing clinical trials in primary brain tumor patients without obvious toxicity, our results are immediately actionable against the TNBC-BM patient population.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR806-specific CAR T-cell therapy • depatuxizumab (ABT-806)
    almost4years
    EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
    P1, N=36, Recruiting, Seattle Children's Hospital | Trial completion date: Jun 2036 --> Jun 2038 | Trial primary completion date: Jun 2021 --> Jun 2023
    Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule)
    |
    EGFR expression
    |
    EGFR806-specific CAR T-cell therapy